Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of L9LS on R21/Matrix-M™ Vaccine Immunogenicity in Healthy Malian Adults and Infants
NCT07208760Phase 2Withdrawn
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Mar 2026
- Primary completion
- Mar 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of L9LS in malaria, sponsored by National Institute of Allergy and Infectious Diseases. Planned start Mar 2026; status: withdrawn.
02
Drugs
L9LS
03
Conditions
malaria
Beyond the preview
Go deeper on NCT07208760.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07208760.